Diversion Control Division, US Department of Justice, Drug Enforcement Administration

Manufacturers Notice of Application - 2007

FR Doc E7-16937 [Federal Register: August 28, 2007 (Volume 72, Number 166)] [Notices] [Page 49315-49316] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr28au07-140]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 20, 2007, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug Schedule
Cathinone (1235)  I
Methcathinone (1237)  I
N-Ethylamphetamine (1475)  I
N,N-Dimethylamphetamine (1480)  I
Aminorex (1585)  I
4-Methylaminorex (cis isomer) (1590)  I
Gamma Hydroxybutyric acid (2010)  I
Methaqualone (2565)  I
Alpha-Ethyltryptamine (7249)  I
Lysergic acid diethylamide (7315)  I
Marihuana (7360)  I
Tetrahydrocannabinols (7370)  I
Mescaline (7381)  I
3,4,5-Trimethoxyamphetamine (7390)  I
4-Bromo-2,5-dimethoxyamphetamine (7391)  I
4-Bromo-2,5-dimethoxyphenethylamine (7392)  I
4-Methyl-2,5-dimethoxyamphetamine (7395)  I
2,5-Dimethoxyamphetamine (7396)  I
2,5-Dimethoxy-4-ethylamphetamine (7399)  I
3,4-Methylenedioxyamphetamine (7400)  I
5-Methoxy-3,4-methylenedioxyamphetamine (7401)  I
N-Hydroxy-3,4-methylendioxyamphetamine (7402)  I
3,4-Methylendioxy-N-ethylamphetamine (7404)  I
3,4-Methylenedioxymethamphetamine (7405)  I
4-Methoxyamphetamine (7411)  I
Alpha-methyltryptamine (7432)  I
Bufotenine (7433)  I
Diethyltryptamine (7434)  I
Dimethyltryptamine (7435)  I
Psilocybin (7437)  I
Psilocyn (7438)  I
Acetyldihydrocodeine (9051)  I
Benzylmorphine (9052)  I
Codeine-N-oxide (9053)  I
Dihydromorphine (9145)  I
Heroin (9200)  I
Hydromorphinol (9301)  I
Methyldihydromorphine (9304)  I
Morphine-N-oxide (9307)  I
Normorphine (9313)  I
Pholcodine (9314)  I
Acetylmethadol (9601)  I
Allylprodine (9602)  I
Alphacetylmethadol except levo-alphacetylmethadol (9603)  I
Alphameprodine (9604)  I
Alphamethadol (9605)  I
Betacetylmethadol (9607)  I
Betameprodine (9608)  I
Betamethadol (9609)  I
Betaprodine (9611)  I
Hydroxypethidine (9627)  I
Noracymethadol (9633)  I
Norlevorphanol (9634)  I
Normethadone (9635)  I
Trimeperidine (9646)  I
Phenomorphan (9647)  I
Para-Fluorofentanyl (9812)  I
3-Methylfentanyl (9813)  I
Alpha-Methylfentanyl (9814)  I
Acetyl-alpha-methylfentanyl (9815)  I
Beta-hydroxyfentanyl (9830)  I
Beta-hydroxy-3-methylfentanyl (9831)  I
Alpha-Methylthiofentanyl (9832)  I
3-Methylthiofentanyl (9833)  I
Thiofentanyl (9835)  I
Amphetamine (1100)  II
Methamphetamine (1105)  II
Phenmetrazine (1631)  II
Methylphenidate (1724)  II
Ambobarbital (2125)  II
Pentobarbital (2270)  II
Secobarbital (2315)  II
Glutethimide (2550)  II
Nabilone (7379)  II
1-Phenylcyclohexylamine (7460)  II
Phencyclidine (7471)  II
1-Piperidinocyclohexane carbonitrile (8603)   II
Alphaprodine (9010)  II
Cocaine (9041)  II
Codeine (9050)  II
Dihydrocodeine (9120)  II
Oxycodone (9143)  II
Hydromorphone (9150)  II
Diphenoxylate (9170)  II
Benzoylecgonine (9180)  II
Ethylmorphine (9190)  II
Hydrocodone (9193)  II
Levomethorphan (9210)  II
Levorphanol (9220)  II
Isomethadone (9226)  II
Meperidine (9230)  II
Methadone (9250)  II
Methadone intermediate (9254)  II
Dextropropoxyphene, bulk (non-dosage forms)(9273)  II
Morphine (9300)  II
Thebaine (9333)  II
Levo-alphacetylmethadol (9648)  II
Oxymorphone (9652)  II
Noroxymorphone (9668)  II
Racemethorphan (9732)  II
Alfentanil (9737)  II
Sufentanil (9740)  II
Fentanyl (9801)  II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 29, 2007.

Dated: August 16, 2007.

Joseph T. Rannazzisi, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7-16937 Filed 8-27-07; 8:45 am]

BILLING CODE 4410-09-P

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility